Middle East And Africa Kidney Cancer Diagnostics Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
Dollars américains 896.76 |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché du diagnostic du cancer du rein au Moyen-Orient et en Afrique, par type de test (imagerie, test de biomarqueur, test sanguin, biopsie, test génétique et autres), stade du cancer (stade I, stade II, stade III et stade IV), type de tumeur (carcinome rénal, carcinome rénal à cellules claires, carcinome rénal à cellules non claires), produit (produits basés sur une plate-forme, produits basés sur des instruments, kits et réactifs et autres consommables), technologie ( hybridation in situ fluorescente , séquençage de nouvelle génération, fluoroimmuno-essai, hybridation génomique comparative, immunohistochimique et autres), application (dépistage, diagnostic et prédictif, pronostic et recherche), utilisateur final (hôpitaux, centres de diagnostic, centres de recherche sur le cancer, instituts universitaires, centres de chirurgie ambulatoire et autres), canal de distribution (appel d'offres direct, ventes au détail et autres), tendances de l'industrie et prévisions jusqu'en 2030.
Analyse et taille du marché du diagnostic du cancer du rein au Moyen-Orient et en Afrique
Le cancer du rein débute lorsque des cellules saines dans l'un ou les deux reins se modifient et se développent de manière incontrôlable, formant une masse appelée tumeur corticale. La tumeur peut être maligne, indolente ou bénigne. Une tumeur maligne est un cancer, ce qui signifie qu'elle peut se développer et se propager à d'autres parties du corps. Une tumeur indolente est également un cancer, mais ce type de tumeur se propage rarement à d'autres parties du corps. Une tumeur bénigne signifie que la tumeur peut croître mais ne pas se propager.
La sensibilisation croissante au cancer du rein au Moyen-Orient et en Afrique a accru la demande pour ce marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent sur le lancement et l'approbation de divers services au cours de cette période cruciale. En outre, l'augmentation des procédures de diagnostic améliorées pour le cancer du rein contribue également à la demande croissante de tests de diagnostic du cancer du rein.
Le marché du diagnostic du cancer du rein au Moyen-Orient et en Afrique devrait croître au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs sur le marché et de la disponibilité de services avancés. Parallèlement à cela, les fabricants sont engagés dans des activités de R&D pour lancer de nouveaux services sur le marché. L'augmentation de la recherche dans le domaine du diagnostic et du développement rénaux devrait encore stimuler la croissance du marché. Cependant, les lésions tissulaires dues à une exposition élevée aux rayonnements des tests d'imagerie devraient entraver la croissance du marché du diagnostic du cancer du rein au Moyen-Orient et en Afrique au cours de la période de prévision.
Selon les analyses de Data Bridge Market Research, le marché du diagnostic du cancer du rein devrait atteindre une valeur de 896,76 millions USD d'ici 2030, à un TCAC de 4,6 % au cours de la période de prévision. L'imagerie représente le segment de type de test le plus important du marché en raison de la demande croissante d'appareils intelligents, et l'augmentation des dépenses de santé a accéléré la demande d'appareils médicaux intelligents.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable pour 2020-2016) |
|
Unités quantitatives |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stage (Stage I, Stage II, Stage III, and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Non Clear Cell Renal Cell Carcinoma), Product (Platform Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others). |
|
Countries Covered |
South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel and the Rest of the Middle East and Africa. |
|
Market Players Covered |
Siemens Healthcare GmbH, Koninklijke Philips N.V., FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Myriad Genetics, Inc., CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Illumina Inc., Ambry Genetics, Invitae Corporation, General Electric Company, Centogene N.V., GenPath, Creative Diagnostics, GeneDx LLC, Blueprint Genetics Oy, BioVendor R&D, and CD Genomics, and BD, among others |
Market Definition
Kidney cancer, commonly known as renal cancer, is a condition in which kidney cells develop into malignant (cancerous) tumors and expand uncontrollably. One of the top 10 most prevalent cancers is kidney cancer. Kidney cancer is fatal, and the diagnosis process also has safety issues; it is not cost-effective. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and systemic therapy. About 40% of kidney growths are tiny, localized masses. Localized refers to a tumor that has not spread from its original location. Kidney masses cannot be detected with regular laboratory procedures. Diagnosis of kidney cancer includes biopsy procedures, blood tests, and Imaging tests. Advanced kidney cancer therapies, like immunotherapy, radiation therapy, etc., are advised. Due to cutting-edge methods, nonsurgical procedures like cryoablation (which freezes cancer cells) and radiofrequency ablation are sometimes used to treat minor kidney tumors (heat cancer cells).
Kidney cancer can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. More than 43,000 men and 25,000 women are diagnosed with kidney and renal pelvis cancer each year, and 9,000 men and 5,000 women pass away as a result of this illness. However, strict regulations and standards for the approval and commercialization of kidney cancer diagnostic products are expected to restrain market growth.
Middle East and Africa Kidney Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Growing Prevalence of Kidney Cancer
All ages can be affected by this type of cancer. Kidney cancer can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. Kidney cancer usually has no signs or symptoms in its early stages. Over time, signs and symptoms may occur, including blood in the urine, which may appear pink, red, or cola-colored, back or side pain that does not go away, loss of appetite, unexplained weight loss, fatigue, and fever. In adults, kidney cancer is the most common type of cancer. Young children are more likely to develop a type of kidney cancer called Wilms tumor. Renal cancer (also known as kidney cancer or renal cell adenocarcinoma) is the 14th most common cancer worldwide. It is 9th among men and 14th among women. In 2020, more than 30,000 new cases of kidney cancer were diagnosed.
Due to various risk factors such as smoking, obesity, high blood pressure (hypertension) or family history of kidney cancer, patients with kidney cancer is rising Middle East and Africa and becoming a significant socio-economic issue. Thus the rising number of patients with kidney cancer increases the demand for kidney cancer diagnostics products which act as a driver in the Middle East and Africa kidney cancer diagnostics market.
- Increase in Diagnostic Procedures for Kidney Cancer
Techniques used to diagnose kidney cancer include ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI) and, sometimes, positron emission tomography (PET) scans. Treatment for kidney cancer with a slow growth rate may involve monitoring. Chemotherapy for malignant is occasionally combined with radiation therapy and stem cell transplant. The increasing cancer rates have been a boosting factor for the increasing diagnostic product approval.
Thus, the rise in diagnostic product approvals has led to an increased number of highly efficient products in the market for kidney cancer diagnosis treatment. This is expected to act as a driver for the growth of the Middle East and Africa kidney cancer diagnostics market.
Opportunity
-
Rising Preference for Preventive Health Check-Ups
Preventive health check-up is preventive actions performed for the initial detection of kidney cancer disease. Also, a rising preference for preventive health check-ups provides a safeguard against likely exposure to any disease in the future.
Awareness to promote screening is the most important component of kidney cancer prevention. The check-up is comprised of the identification of cancer and examinations of risk factors to limit loss at an early stage.
Preventive kidney cancer check-up is performed with the help of various diagnostic test, which includes biopsy, immunohistochemistry, cancer screening, MRI and among others.
People are relatively more prone to kidney cancer diseases. Therefore, they require going through regular check-ups to facilitate physicians develop an understanding of diseases and to provide better treatment to a patient who is suffering from cancer, for the reason rising preference for preventive health check-ups is expected to act as a driver for the growth of Middle East and Africa kidney cancer diagnostics market.
Restraint/Challenge
- Strict Regulations And Standards For The Approval And Commercialization Of Kidney Cancer Diagnostic Products
The stringent regulations for the commercialization of any product in the market are proving to be a big challenge for the manufacturers of cancer diagnostic products Middle East and Africa that have regulations and a different body for the regulatory procedures.
Manufacturers first have to check the CE mark approval for their product's commercialization into the Middle East and Africa market. The stringent regulatory policies are expected to hinder the development of the cancer diagnostic market. The regulatory requirement for approvals of marketing or CE certification and application of laws and regulations could lead to major business changes or paying penalties, including the potential loss of business licenses. The resources and costs required to comply with these laws, rules, and regulations are high.
The regulatory requirement for marketing approvals, declaration of conformity, and the time required for regulatory review may vary for different products. The company which fails to get regulatory approval harms the business because without getting approval or failing to get CE to mark approval on the products, manufacturers are not able to launch their product in the Middle East and Africa market, and for this reason, strict regulations and standards for the approval and commercialization of kidney cancer diagnostic products are expected to act as a restrain for the Middle East and Africa kidney cancer diagnostics market.
Recent Developments
- In November 2022, Koninklijke Philips N.V. announced the Middle East and Africa launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients. It is portable and versatile with good image quality or performance. It is Compatible with Philips ultrasound systems Affiniti and EPIQ transducer. This has helped the company to expand its product portfolio.
- In October 2022, General Electric Company had collaborated with several research institutes like the University of Cambridge Hospitals, Sophia Genetics, and earlier with Optellum to use imaging data in collaboration with Artificial intelligence. This will help to reduce the diagnosing time of several cancers and help to provide personalized care to patients. This has helped the company to widen its horizons in cancer diagnostics.
- In July 2022, Canon Medical Systems USA Inc. announced the completion of the acquisition of NXC Imaging, a medical imaging equipment distributor and service provider located in Minnesota, U.S. This results in expanding the service outreach in the Middle East and Africa market.
Middle East and Africa Kidney Cancer Diagnostics Market Scope
The Middle East and Africa kidney cancer diagnostics market is segmented into eight notable segments based on test type, cancer stage, tumor type, product, application, technology, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Test Type
- IMAGING TEST
- BIOMARKER TEST
- BLOOD TEST
- BIOPSY
- GENETIC TEST
- OTHERS
On the basis of test type, the Middle East and Africa kidney cancer diagnostics market is segmented into imaging, biomarker test, blood test, biopsy, genetic tests, and others.
Cancer Stage
- STAGE I
- STAGE II
- STAGE III
- STAGE IV
On the basis of cancer stage, the Middle East and Africa kidney cancer diagnostics market is segmented into stage I, stage II, stage III and stage IV.
Tumor Type
- RENAL CELL CARCINOMA
- CLEAR CELL RENAL CELL CARCINOMA
- NON-CLEAR CELL RENAL CELL CARCINOMA
On the basis of tumor type, the Middle East and Africa kidney cancer diagnostics market is segmented into renal cell carcinoma, Clear cell renal cell carcinoma, and non-clear cell renal cell carcinoma.
Product
- PLATFORM BASED PRODUCTS
- INSTRUMENT BASED PRODUCTS
- KITS AND REAGENTS
- OTHER CONSUMABLES
On the basis of product, the Middle East and Africa kidney cancer diagnostics market is segmented into instrument-based products, platform-based products, kits and reagents, and other consumables.
Technology
- FLUORESCENT IN SITU HYBRIDIZATION
- NEXT GENERATION SEQUENCING
- FLUOROIMMUNOASSAY
- COMPARATIVE GENOMIC HYBRIDIZATION
- IMMUNOHISTOCHEMICAL
- OTHERS
On the basis of technology, the Middle East and Africa kidney cancer diagnostics market is segmented into fluorescent in situ hybridization, next-generation sequencing, fluorimmunoassay, comparative genomic hybridization, immunohistochemical, and others.
Application
- SCREENING
- DIAGNOSTIC AND PREDICTIVE
- PROGNOSTIC
- RESEARCH
On the basis of application, the Middle East and Africa kidney cancer diagnostics market is segmented into screening, diagnostic and predictive, prognostic, and research.
End User
- HOSPITALS
- CANCER RESEARCH CENTERS
- ACADEMIC INSTITUTES
- DIAGNOSTIC CENTERS
- AMBULATORY SURGICAL CENTERS
- OTHERS
On the basis of end users, the Middle East and Africa kidney cancer diagnostics market is segmented into hospitals, diagnostic centers, cancer research centers, academic institutes, ambulatory surgical centers, and others.
Distribution Channel
- DIRECT TENDERS
- RETAIL SALES
- OTHERS
On the basis of distribution channel, the Middle East and Africa kidney cancer diagnostics market is segmented into direct tender, retail sales and others.
Middle East and Africa Kidney Cancer Diagnostics Market Regional Analysis/Insights
The Middle East and Africa kidney cancer diagnostics market is analyzed and market size information is provided based on country, test type, cancer stage, tumor type, product, application, technology, end user and distribution channel.
The countries covered in this market report are South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel and the Rest of the Middle East and Africa.
South Africa is dominating the market due to the rise in technological advancement in the healthcare devices market.
Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and the challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Kidney Cancer Diagnostics Market Share Analysis
The kidney cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the kidney cancer diagnostics market.
Certains des principaux acteurs opérant sur le marché sont Siemens Healthcare GmbH, Koninklijke Philips NV, FUJIFILM Corporation, Grail, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Myriad Genetics, Inc., CANON MEDICAL SYSTEMS CORPORATION, QIAGEN, Illumina Inc., Ambry Genetics, Invitae Corporation, General Electric Company, Centogene NV, GenPath, Creative Diagnostics, GeneDx LLC, Blueprint Genetics Oy, BioVendor R&D, et CD Genomics, et BD, entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TEST TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
4.3 EPIDEMIOLOGY
4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES
4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES
5 INDUSTRY INSIGHTS
6 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF KIDNEY CANCER
7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER
7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER
7.2 RESTRAINTS
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS
7.3 OPPORTUNITIES
7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE
7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS
7.4 CHALLENGES
7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS
8 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 IMAGING
8.2.1 COMPUTED TOMOGRAPHY
8.2.2 ULTRASOUND
8.2.3 MAGNETIC RESONANCE IMAGING (MRI)
8.2.4 ANGIOGRAPHY
8.2.5 X-RAY
8.2.6 OTHERS
8.3 BLOOD TEST
8.4 BIOPSY
8.4.1 FINE NEEDLE ASPIRATION
8.4.2 NEEDLE CORE BIOPSY
8.5 BIOMARKER TEST
8.5.1 AQUAPORIN 1 (AQP1)
8.5.2 PERILIPIN (PLIN2)
8.5.3 N-METHYLTRANSFERASE (NMNT)
8.5.4 L-PLASTIN (LCP-1)
8.5.5 NM23A
8.6 GENETIC TEST
8.7 OTHERS
9 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE
9.1 OVERVIEW
9.2 STAGE I
9.3 STAGE II
9.4 STAGE III
9.5 STAGE IV
10 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE
10.1 OVERVIEW
10.2 RENAL CELL CARCINOMA
10.2.1 IMAGING
10.2.2 BLOOD TEST
10.2.3 BIOPSY
10.2.4 BIOMARKER TEST
10.2.5 GENETIC TEST
10.2.6 OTHERS
10.3 CLEAR CELL RENAL CELL CARCINOMA
10.3.1 IMAGING
10.3.2 BLOOD TEST
10.3.3 BIOPSY
10.3.4 BIOMARKER TEST
10.3.5 GENETIC TEST
10.3.6 OTHERS
10.4 NON CLEAR CELL RENAL CELL CARCINOMA
10.4.1 PAPILLARY RENAL CELL CARCINOMA
10.4.1.1 IMAGING
10.4.1.2 BLOOD TEST
10.4.1.3 BIOPSY
10.4.1.4 BIOMARKER TEST
10.4.1.5 GENETIC TEST
10.4.1.6 OTHERS
10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA
10.4.2.1 IMAGING
10.4.2.2 BLOOD TEST
10.4.2.3 BIOPSY
10.4.2.4 BIOMARKER TEST
10.4.2.5 GENETIC TEST
10.4.2.6 OTHERS
11 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT
11.1 OVERVIEW
11.2 INSTRUMENT BASED PRODUCTS
11.2.1 IMAGING
11.2.2 BIOPSY
11.3 PLATFORM BASED PRODUCTS
11.3.1 NEXT GENERATION SEQUENCING
11.3.2 MICROARRAYS
11.3.3 PCR
11.3.4 OTHERS
11.4 KITS AND REAGENTS
11.4.1 RENAL CANCER PANELS
11.4.2 RENAL CANCER ANTIBODIES
11.5 OTHER CONSUMABLES
12 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
12.1 OVERVIEW
12.2 FLUORESCENT IN SITU HYBRIDIZATION
12.3 NEXT GENERATION SEQUENCING
12.4 FLUORIMMUNOASSAY
12.5 COMPARATIVE GENOMIC HYBRIDIZATION
12.6 IMMUNOHISTOCHEMICAL
12.7 OTHERS
13 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 SCREENING
13.2.1 INSTRUMENT BASED PRODUCTS
13.2.2 PLATFORM BASED PRODUCTS
13.2.3 KITS AND REAGENTS
13.2.4 OTHER CONSUMABLES
13.3 DIAGNOSTIC AND PREDICTIVE
13.3.1 INSTRUMENT BASED PRODUCTS
13.3.2 PLATFORM BASED PRODUCTS
13.3.3 KITS AND REAGENTS
13.3.4 OTHER CONSUMABLES
13.4 PROGNOSTIC
13.4.1 INSTRUMENT BASED PRODUCTS
13.4.2 PLATFORM BASED PRODUCTS
13.4.3 KITS AND REAGENTS
13.4.4 OTHER CONSUMABLES
13.5 RESEARCH
13.5.1 INSTRUMENT BASED PRODUCTS
13.5.2 PLATFORM BASED PRODUCTS
13.5.3 KITS AND REAGENTS
13.5.4 OTHER CONSUMABLES
14 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 DIAGNOSTIC CENTERS
14.4 CANCER RESEARCH CENTERS
14.5 ACADEMIC INSTITUTES
14.6 AMBULATORY SURGICAL CENTERS
14.7 OTHERS
15 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
15.4 OTHERS
16 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION
16.1 MIDDLE EAST AND AFRICA
16.1.1 SOUTH AFRICA
16.1.2 SAUDI ARABIA
16.1.3 BAHRAIN
16.1.4 U.A.E.
16.1.5 EGYPT
16.1.6 ISRAEL
16.1.7 KUWAIT
16.1.8 OMAN
16.1.9 QATAR
16.1.10 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 CANON MEDICAL SYSTEMS CORPORATION
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY PROFILE
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 KONINKLIJKE PHILIPS N.V.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY PROFILE
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 GENERAL ELECTRIC COMPANY
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY PROFILE
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 SIEMENS HEALTHCARE GMBH
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY PROFILE
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 GRAIL
19.5.1 COMPANY SNAPSHOT
19.5.2 PRODUCT PORTFOLIO
19.5.3 RECENT DEVELOPMENTS
19.6 AMBRY GENETICS
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BIOVENDOR R&D
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 BLUEPRINT GENETICS OY.
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 CD GENOMICS
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 CENTOGENE N.V.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 CREATIVE DIAGNOSTICS
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 FUJIFILM CORPORATION
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 GENEDX, LLC
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENT
19.14 GENPATH, A DIVISION OF BIOREFERENCE LABORATORIES, AN OPKO HEALTH INC. COMPANY
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 ILLUMINA, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 INVITAE CORPORATION
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 LABORATORY CORPORATION OF AMERICA HOLDINGS
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 MYRIAD GENETICS, INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 THERMO FISHER SCIENTIFIC INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENT
19.2 QIAGEN
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
Liste des tableaux
TABLE 1 ESTIMATED NEW CANCER CASES AND DEATHS
TABLE 2 APPROVED DIAGNOSTICS OF KIDNEY CANCER
TABLE 3 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA BLOOD TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA GENETIC TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA STAGE I IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA STAGE II IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA STAGE III IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA STAGE IV IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 31 MIDDLE EAST & AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 32 MIDDLE EAST & AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 35 MIDDLE EAST & AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 36 MIDDLE EAST & AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA OTHER CONSUMABLES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA FLUORIMMUNOASSAY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA COMPARATIVE GENOMIC HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA IMMUNOHISTOCHEMICAL IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA HOSPITALS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA CANCER RESEARCH CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA ACADEMIC INSTITUTES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 65 MIDDLE EAST & AFRICA DIRECT TENDER IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 MIDDLE EAST & AFRICA RETAIL SALES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST & AFRICA OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 79 MIDDLE EAST AND AFRICA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 80 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 81 MIDDLE EAST AND AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 82 MIDDLE EAST AND AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 83 MIDDLE EAST AND AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 84 MIDDLE EAST AND AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 MIDDLE EAST AND AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 86 MIDDLE EAST AND AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 87 MIDDLE EAST AND AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 MIDDLE EAST AND AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 89 MIDDLE EAST AND AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 90 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 91 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 92 MIDDLE EAST AND AFRICA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 93 MIDDLE EAST AND AFRICA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 MIDDLE EAST AND AFRICA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 95 MIDDLE EAST AND AFRICA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 96 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 97 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 98 SOUTH AFRICA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 99 SOUTH AFRICA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 100 SOUTH AFRICA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 101 SOUTH AFRICA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 102 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 103 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 104 SOUTH AFRICA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 SOUTH AFRICA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 SOUTH AFRICA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 107 SOUTH AFRICA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 108 SOUTH AFRICA CHROMPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 109 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 110 SOUTH AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 111 SOUTH AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 112 SOUTH AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 113 SOUTH AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 SOUTH AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 115 SOUTH AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 116 SOUTH AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 117 SOUTH AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 118 SOUTH AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 119 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 120 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 121 SOUTH AFRICA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 122 SOUTH AFRICA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 123 SOUTH AFRICA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 124 SOUTH AFRICA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 125 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 126 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 SAUDI ARABIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 128 SAUDI ARABIA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 129 SAUDI ARABIA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 130 SAUDI ARABIA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 131 SAUDI ARABIA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 132 SAUDI ARABIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 133 SAUDI ARABIA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 134 SAUDI ARABIA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 135 SAUDI ARABIA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 136 SAUDI ARABIA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 137 SAUDI ARABIA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 138 SAUDI ARABIA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 139 SAUDI ARABIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 140 SAUDI ARABIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 141 SAUDI ARABIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 142 SAUDI ARABIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 SAUDI ARABIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 144 SAUDI ARABIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 145 SAUDI ARABIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 146 SAUDI ARABIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 147 SAUDI ARABIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 148 SAUDI ARABIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 149 SAUDI ARABIA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 150 SAUDI ARABIA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 151 SAUDI ARABIA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 152 SAUDI ARABIA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 153 SAUDI ARABIA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 154 SAUDI ARABIA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 155 SAUDI ARABIA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 156 BAHRAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 157 BAHRAIN IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 158 BAHRAIN BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 159 BAHRAIN BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 160 BAHRAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 161 BAHRAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 162 BAHRAIN RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 163 BAHRAIN CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 164 BAHRAIN NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 165 BAHRAIN PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 166 BAHRAIN CHROMPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 167 BAHRAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 168 BAHRAIN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 169 BAHRAIN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 170 BAHRAIN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 171 BAHRAIN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 172 BAHRAIN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 173 BAHRAIN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 174 BAHRAIN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 175 BAHRAIN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 176 BAHRAIN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 177 BAHRAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 178 BAHRAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 179 BAHRAIN SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 180 BAHRAIN DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 BAHRAIN PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 182 BAHRAIN RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 183 BAHRAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 184 BAHRAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 185 U.A.E. KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 186 U.A.E. IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 187 U.A.E. BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 188 U.A.E. BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 189 U.A.E. KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 190 U.A.E. KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 191 U.A.E. RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 192 U.A.E. CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 193 U.A.E. NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 194 U.A.E. PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 195 U.A.E. CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 196 U.A.E. KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 197 U.A.E. INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 198 U.A.E. INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 199 U.A.E. INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 200 U.A.E. PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 201 U.A.E. PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 202 U.A.E. PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 203 U.A.E. KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 204 U.A.E. KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 205 U.A.E. KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 206 U.A.E. KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 207 U.A.E. KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 208 U.A.E. SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 209 U.A.E. DIAGNOSTIC & PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 210 U.A.E. PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 211 U.A.E. RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 212 U.A.E. KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 213 U.A.E. KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 214 EGYPT KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 215 EGYPT IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 216 EGYPT BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 217 EGYPT BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 218 EGYPT KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 219 EGYPT KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 220 EGYPT RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 221 EGYPT CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 222 EGYPT NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 223 EGYPT PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 EGYPT CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 225 EGYPT KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 226 EGYPT INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 227 EGYPT INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 228 EGYPT INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 229 EGYPT PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 230 EGYPT PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 231 EGYPT PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 232 EGYPT KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 233 EGYPT KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 234 EGYPT KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 235 EGYPT KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 236 EGYPT KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 237 EGYPT SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 238 EGYPT DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 EGYPT PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 240 EGYPT RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 241 EGYPT KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 242 EGYPT KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 243 ISRAEL KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 244 ISRAEL IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 245 ISRAEL BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 246 ISRAEL BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 247 ISRAEL KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 248 ISRAEL KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 249 ISRAEL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 250 ISRAEL CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 251 ISRAEL NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 252 ISRAEL PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 253 ISRAEL CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 254 ISRAEL KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 255 ISRAEL INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 256 ISRAEL INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 257 ISRAEL INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 258 ISRAEL PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 259 ISRAEL PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 260 ISRAEL PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 261 ISRAEL KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 262 ISRAEL KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 263 ISRAEL KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 264 ISRAEL KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 265 ISRAEL KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 266 ISRAEL SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 267 ISRAEL DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 268 ISRAEL PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 269 ISRAEL RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 270 ISRAEL KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 271 ISRAEL KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 272 KUWAIT KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 273 KUWAIT IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 274 KUWAIT BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 275 KUWAIT BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 276 KUWAIT KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 277 KUWAIT KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 278 KUWAIT RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 279 KUWAIT CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 280 KUWAIT NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 281 KUWAIT PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 282 KUWAIT CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 283 KUWAIT KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 284 KUWAIT INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 285 KUWAIT INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 286 KUWAIT INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 287 KUWAIT PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 288 KUWAIT PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 289 KUWAIT PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 290 KUWAIT KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 291 KUWAIT KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 292 KUWAIT KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 293 KUWAIT KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 294 KUWAIT KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 295 KUWAIT SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 296 KUWAIT DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 297 KUWAIT PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 298 KUWAIT RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 299 KUWAIT KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 300 KUWAIT KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 301 OMAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 302 OMAN IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 303 OMAN BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 304 OMAN BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 305 OMAN KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 306 OMAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 307 OMAN RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 308 OMAN CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 309 OMAN NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 310 OMAN PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 311 OMAN CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 312 OMAN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 313 OMAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 314 OMAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 315 OMAN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 316 OMAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 317 OMAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 318 OMAN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 319 OMAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 320 OMAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 321 OMAN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 322 OMAN KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 2021-2030 (USD MILLION)
TABLE 323 OMAN KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 324 OMAN SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 325 OMAN DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 326 OMAN PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 327 OMAN RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 328 OMAN KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 329 OMAN KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 330 QATAR KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 331 QATAR IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 332 QATAR BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 333 QATAR BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 334 QATAR KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 335 QATAR KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 336 QATAR RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 337 QATAR CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 338 QATAR NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 339 QATAR PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 340 QATAR CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 341 QATAR KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 342 QATAR INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 343 QATAR INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 344 QATAR INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 345 QATAR PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 346 QATAR PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 347 QATAR PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 348 QATAR KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 349 QATAR KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 350 QATAR KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 351 QATAR KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 352 QATAR KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 353 QATAR SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 354 QATAR DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 355 QATAR PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 356 QATAR RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 357 QATAR KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 358 QATAR KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 359 REST OF MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF KIDNEY CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET
FIGURE 14 KIDNEY CANCER INCIDENCE, BOTH SEXES, BY REGION (2020)
FIGURE 15 KIDNEY CANCER MORTALITY, BOTH SEXES, BY REGION (2020)
FIGURE 16 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022
FIGURE 17 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 18 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030)
FIGURE 19 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE , 2022
FIGURE 21 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, 2023-2030 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, CAGR (2023-2030)
FIGURE 23 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, LIFELINE CURVE
FIGURE 24 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2022
FIGURE 25 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2023-2030 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, CAGR (2023-2030)
FIGURE 27 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, LIFELINE CURVE
FIGURE 28 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2022
FIGURE 29 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 30 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, CAGR (2023-2030)
FIGURE 31 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, LIFELINE CURVE
FIGURE 32 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2022
FIGURE 33 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 34 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 35 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, LIFELINE CURVE
FIGURE 36 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2022
FIGURE 37 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 38 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, CAGR (2023-2030)
FIGURE 39 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, LIFELINE CURVE
FIGURE 40 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2022
FIGURE 41 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION)
FIGURE 42 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030)
FIGURE 43 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 44 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022
FIGURE 45 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 46 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 47 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 49 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 50 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 51 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 52 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 53 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
